Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals ($VRTX), made two open market purchases totaling $3.9 million in the last year, with the latest on August 6, 2025. These rank 209th among 4,983 insiders, above the average of $1.5 million across 3.29 transactions. She also sold shares 13 times for $19.7 million, most recently on February 27, 2026, ranking 683rd out of 11,678 insiders versus the $8.6 million average over 6.37 trades.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 460 | $489.32 | 131,270.0000 | 258,000,000 | 0.35% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 2520 | $493.29 | 125,076.0000 | 258,000,000 | 1.97% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 949 | $491.30 | 127,596.0000 | 258,000,000 | 0.74% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 2725 | $490.54 | 128,545.0000 | 258,000,000 | 2.08% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 3278 | $488.27 | 131,730.0000 | 258,000,000 | 2.43% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 400 | $479.75 | 137,878.0000 | 258,000,000 | 0.29% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 120 | $481.50 | 137,758.0000 | 258,000,000 | 0.09% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 240 | $482.84 | 137,518.0000 | 258,000,000 | 0.17% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 2510 | $487.13 | 135,008.0000 | 258,000,000 | 1.83% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 1725 | $496.95 | 98,278.0000 | 258,000,000 | 1.72% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 5995 | $496.16 | 100,003.0000 | 258,000,000 | 5.66% | 0.00% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 15580 | $495.38 | 105,998.0000 | 258,000,000 | 12.81% | 0.01% |
| Feb. 27, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 3498 | $494.33 | 121,578.0000 | 258,000,000 | 2.80% | 0.00% |
| Feb. 24, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 4981 | $485.11 | 138,278.0000 | 258,000,000 | 3.48% | 0.00% |
| Feb. 17, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 16326 | $0.00 | 149,813.0000 | 258,000,000 | 12.23% | 0.01% |
| Feb. 17, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 6554 | $483.75 | 143,259.0000 | 258,000,000 | 4.37% | 0.00% |
| Feb. 13, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 13041 | $487.76 | 133,487.0000 | 258,000,000 | 8.90% | 0.01% |
| Feb. 10, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 8297 | $468.41 | 146,528.0000 | 258,000,000 | 5.36% | 0.00% |
| Jan. 22, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 11885 | $0.00 | 154,825.0000 | 258,000,000 | 8.31% | 0.00% |
| Jan. 22, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 26972 | $0.00 | 142,940.0000 | 258,000,000 | 23.26% | 0.01% |
| Aug. 6, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | P | Common Stock | 5710 | $389.95 | 115,968.0000 | 257,899,999 | 5.18% | 0.00% |
| Aug. 6, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | P | Common Stock | 4290 | $389.08 | 110,258.0000 | 257,899,999 | 4.05% | 0.00% |
| Feb. 26, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 14079 | $479.61 | 105,915.0000 | 257,899,999 | 11.73% | 0.01% |
| Feb. 24, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 9386 | $483.28 | 119,994.0000 | 257,899,999 | 7.25% | 0.00% |
| Feb. 14, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 6553 | $463.46 | 129,380.0000 | 257,899,999 | 4.82% | 0.00% |
| Feb. 12, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 19015 | $0.00 | 135,933.0000 | 257,899,999 | 16.26% | 0.01% |
| Feb. 10, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 8300 | $467.98 | 116,918.0000 | 257,899,999 | 6.63% | 0.00% |
| Feb. 4, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 20328 | $0.00 | 125,218.0000 | 257,899,999 | 19.38% | 0.01% |
| Feb. 4, 2025 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 29118 | $0.00 | 104,890.0000 | 257,899,999 | 38.43% | 0.01% |
| Nov. 8, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 15198 | $515.00 | 75,772.0000 | 261,000,000 | 16.71% | 0.01% |
| July 30, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 15202 | $505.00 | 90,970.0000 | 260,500,000 | 14.32% | 0.01% |
| July 22, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 15202 | $497.00 | 106,172.0000 | 260,500,000 | 12.52% | 0.01% |
| June 12, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Kewalramani Reshma | Director | M | Restricted Stock Units | 105263 | $0.00 | 0.0000 | 50,032,873 | 100.00% | 0.21% |
| June 12, 2024 | Ginkgo Bioworks Holdings, Inc. | $DNA | Kewalramani Reshma | Director | M | Class A Common Stock | 105263 | $0.00 | 186,002.0000 | 50,032,873 | 130.37% | 0.21% |
| May 24, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | M | Stock Option (Right to Buy) | 1565 | $0.00 | 0.0000 | 260,500,000 | 100.00% | 0.00% |
| May 24, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 1565 | $457.00 | 121,374.0000 | 260,500,000 | 1.27% | 0.00% |
| May 24, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | M | Common Stock | 1565 | $187.53 | 122,939.0000 | 260,500,000 | 1.29% | 0.00% |
| May 20, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | S | Common Stock | 15202 | $447.00 | 121,374.0000 | 260,500,000 | 11.13% | 0.01% |
| Feb. 23, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 9386 | $431.79 | 136,507.0000 | 260,500,000 | 6.43% | 0.00% |
| Feb. 20, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 7019 | $420.58 | 145,893.0000 | 260,500,000 | 4.59% | 0.00% |
| Feb. 16, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 9359 | $424.01 | 152,912.0000 | 260,500,000 | 5.77% | 0.00% |
| Feb. 9, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | F | Common Stock | 8255 | $422.74 | 162,271.0000 | 260,500,000 | 4.84% | 0.00% |
| Feb. 7, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 20327 | $0.00 | 170,526.0000 | 260,500,000 | 13.53% | 0.01% |
| Feb. 6, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 26972 | $0.00 | 150,199.0000 | 260,500,000 | 21.89% | 0.01% |
| Feb. 6, 2024 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Kewalramani Reshma | CEO & President | A | Common Stock | 14516 | $0.00 | 123,227.0000 | 260,500,000 | 13.35% | 0.01% |